Stockreport

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway [Seeking Alpha]

Climb Bio, Inc.  (CLYM) 
PDF CLYM's phase 2 PrisMN trial in pMN, with initial data expected in 2H 2026, is a key catalyst; expansion into SLE and ITP offers additional upside. Budoprutug's versat [Read more]